Slide 1: Esperion Vision 2040: Strategic Acquisition of Corstasis Therapeutics
ESPERION VISION of es - 2040 Tomorrow > Strategic rr f Corstasis i hérapeuttes © 2026 Esperion Therapeutics, Inc. All rights reserved. March 3, 2026
Slide 2: Forward-looking Statements & Disclosures
Forward-looking Statements & Disclosures This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization and business development plans, current
Slide 3: Corstasis Therapeutics Acquisition — Vision 2040 in Action
V | S LS) N Corstasis Therapeutics Acquisition — Vision 2040 in Action! 2040. = — = = — — — — Strengthen and Expand the Build a Diversified, Advance the Next-Generation Bempedoic Acid Franchise Multi-Product Portfolio ACLY Pipeline * Continue to unlock the predicted * Leverage established U.S. comme
Slide 4: Corstasis Therapeutics Acquisition Overview
Corstasis Therapeutics Acquisition Overview Company Summary Transaction Summary * Lead asset, Enbumyst™ (bumetanide nasal spray), ° Esperion to own global rights to Enbumyst and all FDA-approved in September 2025 for adults with pipeline assets edema associated with congestive heart failure, and hep
Slide 5: Strategic Rationale
Strategic Rationale Building on Esperion’s Deep Domain Expertise in Cardiovascular Disease and Expanding Presence in Metabolic, Hepatic and Renal Disease Expands Esperion’s lipid management focus Accelerates double-digit revenue growth with into complementary treatment for edema in high-margin produ
Slide 6: The Growing Heart Failure Epidemic
ESPERION The Growing Heart Failure Epidemic
Slide 7: Congestive Heart Failure: A Growing U.S. Epidemic
Congestive Heart Failure: A Growing U.S. Epidemic ° CHF Affects more than 6.7M U.S. Adults 2 20 years of Age and is Projected to Impact Over 8M Adults 218 Years by 2030 Trends in Demographics and Disparities in CHF-Related Mortality Among Older Adults in the United States, 1999 to 2019 * CHF cost th
Slide 8: Congestive Heart Failure Hospitalizations Driving Significant Healthcare Costs
Congestive Heart Failure Hospitalizations 1 in 4 patients readmitted within 30 days, driving significant healthcare costs Greatest Expenditure for CHF Treatment Estimated to be $8-15B Annually with Most Common Cost Due to Need for IV Diuretic Treatment 4 Million Hospital ~67% of Admissions are for ~
Slide 9: Addressing the Unmet Need
ESPERION Addressing the Unmet Need
Slide 10: Patient Journey
Patient Journey CENTRAL ILLUSTRATION: Congestion Assessment in HF Patient Journey we v Everest score “Everest score. V Laboratory work-up wv Everest score v.NP's point-of-care (aches, Werelactrolytes) v Weight change V Lang/VC eco yi oman Lung/IVC echo v Chest X-ray v Echocardiography v Stevenson Cl
Slide 11: Enbumyst Opportunity for Intervention
Nea! Enbumyst Opportunity for Intervention At Home Treatment for Hospital Prevention . Intervention Period Window Intervention circumvents future hospitalizations Pre-admission and post-discharge (readmission) are targeted opportunities for fluid management intervention Hospitalization for Fluid Man
Slide 12: What Makes Enbumyst Stand Out?
What Makes Enbumyst Stand Out? Developed in collaboration with cardiology experts to address unmet need for nasal option in loop- diuretic therapy Uniqueness Differentiation ¢ First and only nasal spray diuretic * Cost savings based on differentiated pricing ¢ Provides rapid absorption (bypassing GI
Slide 13: Enbumyst vs. Furoscix
Enbumyst vs. Furoscix Aspect Enbumyst Furoscix Enbumyst Advantage Delive Single Use Intranasal Spray (no SubQ Injection Easier compliance; no pain; no In needles) (wearable, Sh infusion) impact to activities of daily living Onset/Efficacy Tmax “1h, ~2L urine, 140 mmol Na Onset ~30 minutes, reduced C
Slide 14: Target Audience
Target Audience Primary Audience re) Cardiologists, CHF Care Teams Key decision makers for managing fluid overload in CHF © Advance Practice Providers (ANPs,PAs) Lead frontline outpatient care decisions for patients with fluid management needs 14 © 2026 Es on Therapeutics, Inc. Alll rights Secondary
Slide 15: Positioned For The Future
ESPERION Positioned For The Future
Slide 16: Multi-Billion Dollar Annual US Market Opportunity
Multi-Billion Dollar Annual US Market Opportunity Revolutionizing Outpatient CHF Management 6.7M 2.1M $2,214 CHF Patients Addressable Average Cost of | CHF Episodes Enbumyst per CHF 7 Episode é iano Thera fy | Reduce Admissions and Readmissions to Improve Outcomes and Lower the Cost of Care Sources:
Slide 17: Portfolio Fit
Portfolio Fit Our Current Synergies & Enbumyst Portfolio Fit Adds Value © NEXLETOL® & NEXLIZET®: * Expands from chronic lipid/CV * Addresses unmet need in outpatient first-in-class oral ATP citrate lyase therapy -> acute congestion (post-discharge, avoid inhibitors congestion/volume management re-ad
Slide 18: The Combined Company
The Combined Company Perfectly situated to attack two of the largest cardiometabolic markets Strong Financial Position Partnerships & Pipeline Triple Combination © Diversified Product Portfolio NEXT-GENERATION ORAL LIPID-LOWERING IPVNEXLETOL COMBINATIONS (bempedoic acid) 180mg tablets . Bempedoic ac
Slide 19: Strong, High Impact Opportunity
Strong, High Impact Opportunity US HF * 6.7M and 15.8M adults affected annually in the US and G7 respectively Landscape + HF represents 33% ($123B) of annual Medicare Part A and B spend a * Limited outpatient options for fluid overload Unmet Nee * No nasal diuretics currently marketed PNefol geet (-
Slide 20: Vision 2040 in Action: A Transformational Leap Forward
VISPON in Action: A Transformational Leap Forward 2040. IPVNEXLETOL —sIINEXLIZET° Enbumyst (Gempedoic acid) 180mg tablets (bempedbic acid /ezetimibe) 180mg/10mg tablets (bumetanide nasal spray) 0.5 mg Diversified Product Portfolio Reach Sustainable Profitability in 2026 Perfectly positioned to aggre
Slide 21: Experienced Leaders, Breakthrough Innovators
Experienced Leaders, Breakthro yy < ! Y < Sheldon Koenig Ben Halladay John Harlow Betty Jean Swartz Glenn Brame Ben Looker, Esq. PORTOLANA €> MERCK Pfizer NOY “melinta Pfizer PORTOLAWA Z zymergen porTOLaye 1LLUM IMORphOSYS bmc saunaxaio U Celgene Genentech GOODWIN SANOFI NOVARTIS <> t Stephen Pinkos
Slide 22: Important Safety Information
ESPERION Important Safety Information
Slide 23: Enbumyst Safety Information
Enbumyst Safety Information ENBUMYST is contraindicated in patients with anuria, who are in hepatic coma and have a history of hypersensitivity to bumetanide. ENBUMYST is a diuretic that may cause fluid, electrolyte, and metabolic abnormalities. Excessive fluid loss can lead to dehydration, decrease
Slide 24: NEXLETOL (bempedoic acid) Important Safety Information
NEXLETOL® (bempedoic acid) Important Safety Information NEXLETOL is indicated. * to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommen
Slide 25: NEXLIZET (bempedoic acid and ezetimibe) Important Safety Information
NEXLIZET® (bempedoic acid and ezetimibe) Important Safety Information NEXLIZET is indicated: + as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including HeFH + bempedoic acid, a component of NEXLIZET, is indicated to reduce the risk of major adverse cardiovasc